Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid beta (Aβ) plaques and neurofibrillary tau-based tangles, beginning decades before symptoms appear and lead to cognitive decline, with individuals progressing from normal cognitive abilities to prodromal AD and ultimately AD dementia (Jack et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.